Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development.

U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Rockville, Maryland, USA.
Annals of internal medicine (Impact Factor: 16.1). 08/2007; 147(2):117-22.
Source: PubMed

ABSTRACT The U.S. Preventive Services Task Force (USPSTF), an independent panel that has provided the gold standard for evidence-based guidelines in prevention for the past 2 decades, continuously refines its methodology. To keep up with the evolving field of evidence- based medicine and to update recommendations in a timely, efficient, and transparent manner, the USPSTF has developed new methods for evidence reviews and recommendation development. This article summarizes the most recent changes in the recommendation development process, including how the USPSTF solicits and prioritizes topics for review, updates evidence reviews and recommendations, and communicates with its audience.


Available from: Evelyn P Whitlock, May 31, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment. Copyright © 2015 Elsevier Inc. All rights reserved.
    Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 03/2015; DOI:10.1016/j.oooo.2015.01.022 · 1.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Screening for presymptomatic disease provides the potential for early intervention and improved outcomes. However, although this practice has potential benefits, it also has potential harms that must be considered. The U.S. Preventive Services Task Force (USPSTF) is a nonfederal panel of experts convened by the Agency for Health Research and Policy to systematically review the evidence for preventive services, including disease screening, and to create evidence-based recommendations for primary care practice in the United States. As rheumatologists contemplate the potential of screening for preclinical disease, understanding the process used by the USPSTF can help guide research efforts supporting such screening. Copyright © 2014 Elsevier Inc. All rights reserved.
    Rheumatic Disease Clinics of North America 11/2014; 40(4). DOI:10.1016/j.rdc.2014.07.016 · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing and timely medical, scientifi c and public health advice relating to immunization. The Public Health Agency of Canada acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientifi c knowledge and is disseminating this document for information purposes. NACI members and liaison members conduct themselves within the context of the Public Health Agency of Canada's Policy on Confl ict of Interest, including yearly declaration of potential confl ict of interest.
    Canada communicable disease report = Relevé des maladies transmissibles au Canada 01/2009; 35(1).